Physician profile
Stephen Gray
NPI 1497969265
$6,737.83
in general payments reported to CMS, 2019-2025
20 companies · $2,552 in 2025
The $2,552 reported for 2025 was more than what 84% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $120 · 2022: $768 · 2023: $405 · 2024: $2,772 · 2025: $2,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,134 · Food and Beverage: $2,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,133.96 |
| Food and Beverage | $2,594.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Transmedics, INC. | $3,133.96 | 2024-2025 | Organ Care System |
| Boston Scientific Corporation | $718.03 | 2022-2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Abbvie INC. | $632.75 | 2019-2025 | |
| Medtronic, INC. | $390.88 | 2022-2024 | Sonicision |
| Dilon Technologies, INC. | $342.44 | 2025 | Hemoblast Bellows |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246.67 | 2023-2025 | Xifaxan |
| Shionogi INC | $220.34 | 2024-2025 | Fetroja |
| Madrigal Pharmaceuticals | $207.10 | 2024-2025 | Rezdiffra |
| Veloxis Pharmaceuticals, INC. | $200.53 | 2022-2024 | Envarsus |
| Gilead Sciences, INC. | $172.31 | 2024-2025 | Livdelzi |
| Alexion Pharmaceuticals, INC. | $91.06 | 2023-2024 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $87.87 | 2023-2025 | Terlivaz |
| Baxter Healthcare | $63.37 | 2023 | Tisseel, Floseal |
| Takeda Pharmaceuticals U.S.A., INC. | $52.92 | 2022 | |
| Intercept Pharmaceuticals, INC. | $44.95 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $31.55 | 2024 | Rezzayo, Vabomere |
| Astellas Pharma US INC | $30.40 | 2025 | Cresemba |
| Ethicon US, LLC | $28.22 | 2025 | Surgicel Nu-Knit, Prolene, Evarrest |
| Teleflex LLC | $23.09 | 2023 | Quikclot |
| Stryker Corporation | $19.39 | 2023 | Spy-Phi System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.